SIRT3 and prostate cancer: In human prostate tumours, the androgen receptor binds to its coregulator, steroid receptor coactivator‐2, to recruit HDAC2 to the SIRT3 promoter, inhibiting SIRT3 transcription, subsequently increasing the level of the aconitase acetylation, significantly enhancing ACO2 activity, and promoting the progression of advanced prostate cancer.256